{"nctId":"NCT00105989","briefTitle":"Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder","startDateStruct":{"date":"2005-03"},"conditions":["Depressive Disorder, Major"],"count":514,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Duloxetine"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Duloxetine","otherNames":["LY248686","Cymbalta"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must be at least 18 years old.\n* Patient must be diagnosed with depression and have had previous episodes of depression.\n* Patient must sign informed consent.\n\nExclusion Criteria:\n\n* Female and pregnant or breastfeeding.\n* History of bipolar disorder, schizophrenia, or other psychotic disorders.\n* Suffer from a serious medical illness (other than depression) or abnormal laboratory result that would require a change in medication, intervention, or hospitalization.\n* Have been treated with a medication called monoamine oxidase inhibitor (MAOI) within 14 days of the start of the study, or potential need to use a MAOI within 5 days of finishing the study.\n* Have taken an antidepressant called fluoxetine within 30 days of the start of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Depressive Recurrence After Time (t) in Days","description":"Recurrence: Clinical Global Impression-Severity (CGI-S) score \\>=4 and met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD); had 3 consecutive visits where re-emergence criteria met; had total of 10 visits where re-emergence criteria was satisfied; discontinued due to lack of efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null},{"groupId":"OG001","value":"2.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":null},{"groupId":"OG001","value":"2.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":null},{"groupId":"OG001","value":"2.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":null},{"groupId":"OG001","value":"3.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":null},{"groupId":"OG001","value":"12.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.33","spread":null},{"groupId":"OG001","value":"21.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.58","spread":null},{"groupId":"OG001","value":"25.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.34","spread":null},{"groupId":"OG001","value":"28.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.89","spread":null},{"groupId":"OG001","value":"28.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.69","spread":null},{"groupId":"OG001","value":"28.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":null},{"groupId":"OG001","value":"29.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.32","spread":null},{"groupId":"OG001","value":"32.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.32","spread":null},{"groupId":"OG001","value":"34.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.32","spread":null},{"groupId":"OG001","value":"34.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.23","spread":null},{"groupId":"OG001","value":"34.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.03","spread":null},{"groupId":"OG001","value":"35.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence Count","description":"Number of participants who experienced a depressive recurrence at any time during the double-blind maintenance therapy phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days","description":"Worsening occurs if patient had a \\>=50% increase from baseline on the 17-Item Hamilton Depression Rating Scale (HAMD-17) total score and a Clinical Global Impression-Severity (CGI-S) score \\>=3 at any time during the double-blind maintenance therapy phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":null},{"groupId":"OG001","value":"1.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":null},{"groupId":"OG001","value":"1.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.53","spread":null},{"groupId":"OG001","value":"7.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.63","spread":null},{"groupId":"OG001","value":"9.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.89","spread":null},{"groupId":"OG001","value":"22.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.99","spread":null},{"groupId":"OG001","value":"31.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.48","spread":null},{"groupId":"OG001","value":"35.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.02","spread":null},{"groupId":"OG001","value":"40.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.61","spread":null},{"groupId":"OG001","value":"42.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.19","spread":null},{"groupId":"OG001","value":"44.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.57","spread":null},{"groupId":"OG001","value":"45.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.04","spread":null},{"groupId":"OG001","value":"45.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.88","spread":null},{"groupId":"OG001","value":"45.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.88","spread":null},{"groupId":"OG001","value":"46.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.88","spread":null},{"groupId":"OG001","value":"49.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.65","spread":null},{"groupId":"OG001","value":"51.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Loss of Response at Any Time","description":"Loss of response was defined as a HAMD-17 total score \\>9 and a CGI-Severity score \\>2 at any one time during the double-blind maintenance phase of the study regardless of whether or not they subsequently regained response or not.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases","description":"The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.07","spread":"3.55"},{"groupId":"OG001","value":"6.64","spread":"2.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.37","spread":"6.03"},{"groupId":"OG001","value":"-0.61","spread":"5.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Maintenance Phase","description":"The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (absent, mild, moderate, severe, very severe) or a 3-point scale (absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.53"},{"groupId":"OG001","value":"4.36","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Acute and Continuation Phases","description":"Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.49","spread":"0.60"},{"groupId":"OG001","value":"1.83","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"1.08"},{"groupId":"OG001","value":"-0.07","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase","description":"Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.10"},{"groupId":"OG001","value":"0.84","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases","description":"A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":"0.86"},{"groupId":"OG001","value":"1.76","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase","description":"A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.11"},{"groupId":"OG001","value":"2.34","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases","description":"Core and Maier subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier). Higher numbers indicate more severe symptoms. Anxiety/Somatization subscale assesses severity of anxiety (0-18). Retardation subscale assesses dysfunction in mood and work (0-14). Sleep subscale assesses insomnia (0-6). Depressed Mood Item (0-4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.71","spread":"1.99"},{"groupId":"OG001","value":"2.51","spread":"1.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.52","spread":"2.63"},{"groupId":"OG001","value":"-0.11","spread":"2.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.81","spread":"1.78"},{"groupId":"OG001","value":"2.00","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.97","spread":"2.69"},{"groupId":"OG001","value":"-0.29","spread":"2.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.44","spread":"1.95"},{"groupId":"OG001","value":"2.91","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.46","spread":"3.29"},{"groupId":"OG001","value":"-0.29","spread":"2.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.76","spread":"1.53"},{"groupId":"OG001","value":"2.43","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.61","spread":"2.37"},{"groupId":"OG001","value":"-0.48","spread":"2.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":"1.59"},{"groupId":"OG001","value":"1.11","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.37","spread":"1.92"},{"groupId":"OG001","value":"-0.07","spread":"1.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"0.58"},{"groupId":"OG001","value":"0.64","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"0.98"},{"groupId":"OG001","value":"-0.05","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Maintenance Phase","description":"Core and Maier subscales assess symptoms of depression (scores:0-20=Core; 0-24=Maier). Higher numbers indicate more severe symptoms. Anxiety/Somatization subscale assesses severity of anxiety (0-18). Retardation subscale assesses dysfunction in mood and work (0-14). Sleep subscale assesses insomnia (0-6). Depressed Mood item (0-4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.20"},{"groupId":"OG001","value":"1.54","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.22"},{"groupId":"OG001","value":"1.74","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.29"},{"groupId":"OG001","value":"2.25","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"0.20"},{"groupId":"OG001","value":"1.49","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.12"},{"groupId":"OG001","value":"0.71","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.09"},{"groupId":"OG001","value":"0.67","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase","description":"VAS for pain consists of 6 questions that assess overall pain, headache, back pain, shoulder pain, pain interference with daily activities, and pain while awake. Participant rates pain on a 100 millimeter (mm) line between two anchors (0 = no pain and 100 = very severe pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.36","spread":"26.16"},{"groupId":"OG001","value":"17.29","spread":"20.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.34","spread":"26.95"},{"groupId":"OG001","value":"1.16","spread":"21.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.74","spread":"28.08"},{"groupId":"OG001","value":"14.80","spread":"20.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.83","spread":"28.04"},{"groupId":"OG001","value":"0.04","spread":"21.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.79","spread":"27.80"},{"groupId":"OG001","value":"15.61","spread":"22.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.64","spread":"25.66"},{"groupId":"OG001","value":"-0.00","spread":"20.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.06","spread":"27.23"},{"groupId":"OG001","value":"13.49","spread":"21.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.47","spread":"24.25"},{"groupId":"OG001","value":"-0.39","spread":"20.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.28","spread":"28.31"},{"groupId":"OG001","value":"15.59","spread":"21.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.79","spread":"29.77"},{"groupId":"OG001","value":"1.00","spread":"21.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.18","spread":"29.29"},{"groupId":"OG001","value":"19.22","spread":"25.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.66","spread":"31.22"},{"groupId":"OG001","value":"0.06","spread":"25.61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase","description":"VAS for pain consists of 6 questions that assess overall pain, headache, back pain, shoulder pain, pain interference with daily activities, and pain while awake. Participant rates pain on a 100 millimeter (mm) line between two anchors (0 = no pain and 100 = very severe pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.92","spread":"1.78"},{"groupId":"OG001","value":"4.57","spread":"1.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":"1.72"},{"groupId":"OG001","value":"2.80","spread":"1.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"1.65"},{"groupId":"OG001","value":"3.40","spread":"1.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"1.55"},{"groupId":"OG001","value":"3.02","spread":"1.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":"1.74"},{"groupId":"OG001","value":"2.81","spread":"1.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"2.10"},{"groupId":"OG001","value":"4.69","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases","description":"The Somatic subscale consists of 23 items to be completed by the patient that focus on somatic symptoms. Question answers are either yes/no or true/false. Negative response is scored at 1; positive response is scored as 0. Total Somatic subscale scores range from 0-23, where higher scores indicate greater symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.64","spread":"5.09"},{"groupId":"OG001","value":"6.88","spread":"5.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.37","spread":"5.42"},{"groupId":"OG001","value":"-0.35","spread":"4.80"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase","description":"The Somatic subscale consists of 23 items to be completed by the patient that focus on somatic symptoms. Question answers are either yes/no or true/false. Negative response is scored at 1; positive response is scored as 0. Total Somatic subscale scores range from 0-23, where higher scores indicate greater symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"0.39"},{"groupId":"OG001","value":"0.81","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Acute and Continuation Phases","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total (Global) scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Individual Item scores range from 0 to 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.30","spread":"6.58"},{"groupId":"OG001","value":"10.72","spread":"7.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.88","spread":"8.06"},{"groupId":"OG001","value":"-2.01","spread":"7.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.52","spread":"2.52"},{"groupId":"OG001","value":"3.64","spread":"2.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.61","spread":"2.87"},{"groupId":"OG001","value":"-0.71","spread":"2.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"2.42"},{"groupId":"OG001","value":"3.50","spread":"2.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.69","spread":"2.90"},{"groupId":"OG001","value":"-0.64","spread":"2.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.35","spread":"2.44"},{"groupId":"OG001","value":"3.54","spread":"2.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.59","spread":"3.07"},{"groupId":"OG001","value":"-0.63","spread":"2.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total (Global) scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Individual Item scores range from 0 to 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.71"},{"groupId":"OG001","value":"2.06","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.26"},{"groupId":"OG001","value":"0.83","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.25"},{"groupId":"OG001","value":"0.56","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.25"},{"groupId":"OG001","value":"0.67","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase","description":"Assesses general quality of life. 36 questions covering 8 health domains. Each subscale is scored by summing the individual items and transforming scores into a 0-100 scale, with higher scores indicating better health status or functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.55","spread":"9.46"},{"groupId":"OG001","value":"48.05","spread":"8.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.86","spread":"8.66"},{"groupId":"OG001","value":"0.03","spread":"7.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.93","spread":"8.76"},{"groupId":"OG001","value":"39.83","spread":"10.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.67","spread":"11.77"},{"groupId":"OG001","value":"3.98","spread":"12.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.59","spread":"4.75"},{"groupId":"OG001","value":"26.28","spread":"4.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"4.40"},{"groupId":"OG001","value":"0.28","spread":"3.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":"2.45"},{"groupId":"OG001","value":"8.61","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"2.50"},{"groupId":"OG001","value":"0.07","spread":"2.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.24","spread":"1.47"},{"groupId":"OG001","value":"6.48","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"1.78"},{"groupId":"OG001","value":"0.20","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"0.80"},{"groupId":"OG001","value":"4.65","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"1.31"},{"groupId":"OG001","value":"0.34","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.66","spread":"3.62"},{"groupId":"OG001","value":"17.03","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"3.74"},{"groupId":"OG001","value":"0.58","spread":"3.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.62","spread":"4.13"},{"groupId":"OG001","value":"19.60","spread":"4.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"5.31"},{"groupId":"OG001","value":"1.30","spread":"5.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":"1.74"},{"groupId":"OG001","value":"7.05","spread":"1.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":"2.04"},{"groupId":"OG001","value":"0.65","spread":"2.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.85","spread":"3.26"},{"groupId":"OG001","value":"13.84","spread":"3.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.51","spread":"4.22"},{"groupId":"OG001","value":"0.84","spread":"4.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.88","spread":"0.85"},{"groupId":"OG001","value":"3.03","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.95"},{"groupId":"OG001","value":"-0.01","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":"0.99"},{"groupId":"OG001","value":"2.37","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"1.28"},{"groupId":"OG001","value":"-0.34","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase","description":"Assesses general quality of life. 36 questions covering 8 health domains. Each subscale is scored by summing the individual items and transforming scores into a 0-100 scale, with higher scores indicating better health status or functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.70"},{"groupId":"OG001","value":"0.33","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"1.11"},{"groupId":"OG001","value":"-5.74","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.28"},{"groupId":"OG001","value":"-0.07","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.22"},{"groupId":"OG001","value":"-0.19","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.14"},{"groupId":"OG001","value":"-0.41","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.11"},{"groupId":"OG001","value":"-0.46","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.33"},{"groupId":"OG001","value":"-0.61","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.49"},{"groupId":"OG001","value":"-2.60","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.18"},{"groupId":"OG001","value":"-0.50","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"0.38"},{"groupId":"OG001","value":"-1.38","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"},{"groupId":"OG001","value":"0.08","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.09"},{"groupId":"OG001","value":"0.34","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases","description":"Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.03"},{"groupId":"OG001","value":"-0.00","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.03"},{"groupId":"OG001","value":"-0.03","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.04"},{"groupId":"OG001","value":"-0.00","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.02"},{"groupId":"OG001","value":"0.01","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.07"},{"groupId":"OG001","value":"-0.07","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase","description":"Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.00"},{"groupId":"OG001","value":"-0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.00"},{"groupId":"OG001","value":"-0.01","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.01"},{"groupId":"OG001","value":"-0.01","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.01"},{"groupId":"OG001","value":"-0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.02"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases","description":"Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.10"},{"groupId":"OG001","value":"0.36","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.06"},{"groupId":"OG001","value":"0.01","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Maintenance Phase","description":"Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.01"},{"groupId":"OG001","value":"-0.00","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase","description":"Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"2.07"},{"groupId":"OG001","value":"2.67","spread":"2.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"2.25"},{"groupId":"OG001","value":"-0.52","spread":"2.01"}]}]}]},{"type":"SECONDARY","title":"Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Maintenance Phase","description":"Measures direct and indirect costs. Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Patients self-report on number of days over the past month that they have been either late to work, missed work, or missed usual activities due to symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.28"},{"groupId":"OG001","value":"-0.75","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)","description":"A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.57","spread":"4.88"},{"groupId":"OG001","value":"17.26","spread":"4.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"5.08"},{"groupId":"OG001","value":"-0.67","spread":"3.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.47","spread":"2.19"},{"groupId":"OG001","value":"7.16","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"2.32"},{"groupId":"OG001","value":"-0.39","spread":"1.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.91","spread":"1.20"},{"groupId":"OG001","value":"3.68","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.30"},{"groupId":"OG001","value":"-0.21","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.56","spread":"1.11"},{"groupId":"OG001","value":"3.48","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"1.17"},{"groupId":"OG001","value":"-0.18","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","spread":"1.13"},{"groupId":"OG001","value":"3.27","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"1.15"},{"groupId":"OG001","value":"-0.04","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":"1.10"},{"groupId":"OG001","value":"3.60","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"1.30"},{"groupId":"OG001","value":"-0.15","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.36","spread":"1.17"},{"groupId":"OG001","value":"3.32","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.29"},{"groupId":"OG001","value":"-0.15","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)","description":"A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.41","spread":"5.17"},{"groupId":"OG001","value":"19.31","spread":"4.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"3.91"},{"groupId":"OG001","value":"-0.99","spread":"4.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.31","spread":"2.08"},{"groupId":"OG001","value":"8.42","spread":"2.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"1.91"},{"groupId":"OG001","value":"-0.56","spread":"1.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.92","spread":"1.12"},{"groupId":"OG001","value":"4.34","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.05"},{"groupId":"OG001","value":"-0.31","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.40","spread":"1.13"},{"groupId":"OG001","value":"4.08","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"1.07"},{"groupId":"OG001","value":"-0.25","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.97","spread":"1.26"},{"groupId":"OG001","value":"3.57","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.98"},{"groupId":"OG001","value":"-0.10","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.33","spread":"1.19"},{"groupId":"OG001","value":"4.06","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"1.02"},{"groupId":"OG001","value":"-0.28","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":"1.39"},{"groupId":"OG001","value":"3.58","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.18"},{"groupId":"OG001","value":"-0.10","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Males)","description":"A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.47"},{"groupId":"OG001","value":"-0.77","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.22"},{"groupId":"OG001","value":"0.03","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.13"},{"groupId":"OG001","value":"-0.02","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.12"},{"groupId":"OG001","value":"0.07","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.14"},{"groupId":"OG001","value":"-0.10","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.14"},{"groupId":"OG001","value":"-0.43","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.11"},{"groupId":"OG001","value":"-0.04","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Females)","description":"A 5-item patient-rated scale measuring 5 domains: sexual drive, arousal (subjective excitement), lubrication/erection (physiological excitement), ability to reach orgasm, orgasm satisfaction. Higher score means worse dysfunction. Total score range is 5-30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"4.14"},{"groupId":"OG001","value":"-0.47","spread":"4.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.90"},{"groupId":"OG001","value":"0.34","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"1.11"},{"groupId":"OG001","value":"0.18","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.95"},{"groupId":"OG001","value":"0.16","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.92"},{"groupId":"OG001","value":"-0.15","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.96"},{"groupId":"OG001","value":"-0.15","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"1.25"},{"groupId":"OG001","value":"-0.40","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.74","spread":"16.25"},{"groupId":"OG001","value":"74.22","spread":"15.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"2.12"},{"groupId":"OG001","value":"0.88","spread":"3.29"}]}]}]},{"type":"SECONDARY","title":"Vital Signs - Change From Baseline to Endpoint in Weight - Maintenance Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"0.36"},{"groupId":"OG001","value":"0.39","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.76","spread":"9.26"},{"groupId":"OG001","value":"72.79","spread":"9.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"9.18"},{"groupId":"OG001","value":"1.75","spread":"10.39"}]}]}]},{"type":"SECONDARY","title":"Vital Signs - Change From Baseline to Endpoint in Pulse - Maintenance Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"0.76"},{"groupId":"OG001","value":"-1.72","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.03","spread":"14.65"},{"groupId":"OG001","value":"124.72","spread":"13.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"12.62"},{"groupId":"OG001","value":"0.77","spread":"12.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.52","spread":"9.54"},{"groupId":"OG001","value":"78.28","spread":"9.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"8.68"},{"groupId":"OG001","value":"-0.57","spread":"9.18"}]}]}]},{"type":"SECONDARY","title":"Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":"13.44"},{"groupId":"OG001","value":"-1.11","spread":"11.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"9.72"},{"groupId":"OG001","value":"-0.11","spread":"8.69"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.05","spread":"3.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"2.90"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103.73","spread":"2.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"2.81"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.25","spread":"36.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"20.53"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.81","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"261.08","spread":"60.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.23","spread":"40.22"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.21","spread":"2.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"2.96"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.59","spread":"4.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"4.11"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"297.05","spread":"81.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.64","spread":"49.42"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.43","spread":"3.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"2.81"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.41","spread":"2.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"2.93"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.68","spread":"5.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"3.84"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","spread":"0.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.13","spread":"24.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"17.11"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.73","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.47"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.40","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.61","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.73","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.33","spread":"5.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"4.00"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.47","spread":"3.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"3.77"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.81","spread":"11.56"},{"groupId":"OG001","value":"22.12","spread":"11.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"15.40"},{"groupId":"OG001","value":"-0.38","spread":"12.53"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":"0.10"},{"groupId":"OG001","value":"2.43","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.10"},{"groupId":"OG001","value":"-0.01","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.40","spread":"0.72"},{"groupId":"OG001","value":"5.47","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.71"},{"groupId":"OG001","value":"0.03","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.68","spread":"0.91"},{"groupId":"OG001","value":"5.74","spread":"2.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.18"},{"groupId":"OG001","value":"0.62","spread":"1.67"}]}]}]},{"type":"SECONDARY","title":"Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5},"commonTop":["Headache","Hyperhidrosis","Nasopharyngitis","Back pain","Dry mouth"]}}}